Aurora Cannabis (ACB) Stock Price & Analysis
ACB Stock Chart & Stats
- Day’s Range
- $3.98 - $4.09
- 52-Week Range
- $2.56 - $6.36
- Previous Close
- $4.08
- Volume
- 1.41M
- Average Volume (3M)
- 998.00K
- Market Cap
- $266.28M
- Enterprise Value
- $117.20M
- Total Cash (Recent Filing)
- $149.12M
- Total Debt (Recent Filing)
- $22.68M
- Price to Earnings (P/E)
- ―
- Beta
- 1.17
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
International Medical Growth
Strong international medical growth and a rising share of revenue generated outside Canada indicate expanding access to regulated markets. This geographic diversification can reduce dependence on Canadian demand while supporting longer-term scale, market share, and revenue resilience.
Margin And Production Advantages
A 58% adjusted gross margin, combined with genetics that may lift yields by up to 40% without a proportional cost increase, supports durable operating leverage. These advantages can strengthen competitiveness and help sustain margins as international volumes expand.
Debt-Free Balance Sheet
Nearly $150 million of liquidity and no debt provide meaningful financial flexibility for capacity expansion, acquisitions, and market development. The absence of debt also limits refinancing pressure, giving Aurora greater ability to absorb volatility while pursuing its growth strategy.
Bears Say
Declining Revenue And Persistent Losses
The revenue decline and continuing operating and net losses show that Aurora has not yet established durable earnings power. Until growth and profitability stabilize together, the company may have less internal capacity to fund expansion and greater exposure to execution setbacks.
Weak And Deteriorating Cash Generation
Negative operating and free cash flow indicate that the business is not currently self-funding, despite its cash reserves. If the burn persists, liquidity could be consumed by operations, reducing flexibility for investment and increasing the importance of a successful turnaround.
Canadian Reimbursement And Consumer Exit Headwinds
The reimbursement reduction directly pressures Canadian medical revenue and adjusted gross profit, while the consumer-business exit reduces revenue diversification. Together, these changes can weigh on reported growth and make Aurora more dependent on international execution.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis’s price range in the past 12 months?
What is Aurora Cannabis’s market cap?
When is Aurora Cannabis’s upcoming earnings report date?
How were Aurora Cannabis’s earnings last quarter?
Is Aurora Cannabis overvalued?
Does Aurora Cannabis pay dividends?
What is Aurora Cannabis’s EPS estimate?
How many shares outstanding does Aurora Cannabis have?
What happened to Aurora Cannabis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aurora Cannabis?
What is the TipRanks Smart Score and how is it calculated?
Aurora Cannabis Stock Smart Score
Company Description
Aurora Cannabis
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Miguel Martin
- Employees
- 1,028
- Website
- www.auroramj.com
- Address
- 90B Street SW, Edmonton, AB, T6X 1V8, CA
Aurora Cannabis (ACB) Earnings & Revenues
ACB Company Deck
ACB Earnings Call
Earnings Call SentimentNeutral
The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.
View all ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 10 | 0 | 2 |
